Company intelligence / Profile preview
Kelifarma
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
Overview
Kelifarma (KELI Therapeutics) focuses on developing advanced cellular therapies using a proprietary bioprocess cell platform. Their technology has demonstrated promising scientific results in vitro, ex vivo, and in vivo non-clinical models. The company emphasizes scalable GMP-compliant manufacturing but has not yet reported clinical trial outcomes[2][4].
- Therapeutic areas
- Other
- Modalities
- Cell therapyAdvanced therapeutic medicinal product (ATMP)
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Kelifarma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kelifarma.